Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Health https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ The Chinese vaccine Covid-19, given to a million people: Officially

The Chinese vaccine Covid-19, given to a million people: Officially

BEIJING: The Covid-19 vaccine, developed by a state-owned Chinese pharmaceutical company, has been given to about a million people under the government’s emergency scheme, the company’s chairman said.
“In terms of emergency use, the vaccines have been given to nearly a million people and there has not been a single case of a serious adverse event. “People had only mild symptoms,” said Liu Jinzheng, chairman of China’s National Pharmaceutical Group (Sinopharm).
“So far, our entire progress, from research to clinical trials to production and emergency use, has been world-leading,” the Hong Kong-based South China Morning Post said on Thursday, quoted by Liu in front of a Chinese digital media publication.
His comments came amid criticism that Chinese companies had not published clinical data from vaccine studies.
In addition to the recipients of the Sinopharm samples, Zhejiang authorities said they had made the Covid-1
9 vaccine, developed by the private pharmaceutical company Sinovac Biotec, available to high-risk groups in the eastern Chinese province under the emergency scheme.
Meanwhile, Infectious Diseases Journal Lancet says the candidate for the inactivated Chinese vaccine, Covid-19, has been shown to be safe and tolerable and can elicit a rapid immune response.
The level of antibodies induced by the vaccine was lower than in people who recovered from Covid-19, as long as it was able to protect the human body from infections caused by the virus, the state Xinhua said, citing the findings of Lancet.
The CoronaVac vaccine was developed by the Chinese manufacturer of biopharmaceuticals Sinovac Biotech.
It has been tested in randomized, double-blind and placebo-controlled phase 1 and phase 2 clinical trials involving more than 700 healthy adults aged 18 to 59 years.
Vaccination is carried out in two doses taken at 14-day intervals, and the vaccine candidate is effective, making it suitable for emergency use in the face of a pandemic, said Zhu Fengkai, one of the authors of the findings.
Zhu added that further research is needed to verify the duration of the immune response elicited by vaccination.
The vaccine applicant is currently undergoing phase 3 clinical trials to confirm its efficacy.

Source link